Efficacy, Safety, and Tolerability of Oral Eletriptan for Treatment of Acute Migraine

PHASE3CompletedINTERVENTIONAL

Enrollment

1,334

Participants

Timeline

Start Date

July 31, 1996

Primary Completion Date

December 31, 1997

Study Completion Date

December 31, 1997

Conditions

Migraine With or Without Aura

Interventions

DRUG

Placebo

matching placebo

DRUG

Eletriptan 20 mg

20mg oral

DRUG

Eletriptan 40 mg

40mg oral

DRUG

Eletriptan 80 mg

80mg oral

All Listed Sponsors

lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT01978496 - Efficacy, Safety, and Tolerability of Oral Eletriptan for Treatment of Acute Migraine | Biotech Hunter | Biotech Hunter